Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07545291

A Spiritual Health Intervention (PATH) for Improving Spiritual, Religious and Emotional Distress in Cancer Patients

This clinical trial tests the feasibility and effectiveness of a spiritual health intervention (Personal Archetypes Toward Healing Trial [PATH]) for improving spiritual, religious and existential distress in patients with cancer. Many patients with cancer find their diagnosis to elicit challenges to their sense of connection, meaning, and purpose. This distress can significantly impact their quality of life. However, spiritual care interventions are often overlooked. PATH builds on multiple theories and therapeutic practices such as role-playing, archetype psychology, cognitive theory, emotion regulation therapy, and dignity therapy. PATH sessions cover topics such as individuation, intrapersonal meaning and worth, intrapersonal distress and faith, interpersonal distress and faith, and transpersonal distress and faith. The PATH intervention may help cancer patients shift their perspectives and access new insights for working through their spiritual, religious and existential distress.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location contact

RaeAnne Wiseman

CONTACT

[email protected]

206-606-8215

RaeAnne Wiseman

PRINCIPAL_INVESTIGATOR

About this study

OUTLINE:

Patients attend 1 individual PATH session with the interventionist on day 1 and then attend group PATH workshop sessions weekly for 5 sessions (days 7, 14, 21, 28, and 35).

After completion of study intervention, patients are followed up on days 42 and 84.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years of age or older
  • English speaking
  • Able to provide informed consent
  • Current diagnosis of cancer at any stage, engaged in active treatment or surveillance at Fred Hutch Cancer Center
  • Scores of "Somewhat" or above on at least 1 item the Religious and Spiritual Struggles scale (RSS-5) (e.g., Somewhat = 3 on a 1-to-5 Likert scale)

Exclusion criteria

  • Non-oncology Fred Hutch patients

Treatment and study plan

Spiritual Therapy

Procedure

Attend PATH workshops

Survey Administration

Other

Ancillary studies

interview

Other

Ancillary studies

Primary outcomes

  1. Accrual rates (feasibility) (Aim 1)

    Time frame: At time of enrollment

    Feasibility will be examined by conducting frequency and descriptive statistics for enrollment rates. The benchmark for feasibility is ≥ 50% of screened eligible patients enroll in the study. To test this, will perform a one-sample proportion test to examine if the proportion of participants meeting the benchmark for feasibility is significantly higher than 0.50. Feasibility process outcomes will be analyzed to determine whether the intervention is feasible for future dissemination and implementation efforts and recruitment of a full-scale randomized controlled trial.

  2. Rates of intervention completion (feasibility) (Aim 1)

    Time frame: Up to day 84

    Intervention completion metrics will include all 6 intervention sessions as well as both follow-up timepoints (days 42 and 84). Patients will be required to attend at least 70% of all sessions (5 of 6). Feasibility will be examined by conducting frequency and descriptive statistics for intervention completion. The benchmark for feasibility is ≥ 70% of enrolled patients completing the intervention. To test this, will perform a one-sample proportion test to examine if the proportion of participants meeting the benchmark for feasibility is significantly higher than 0.70. Feasibility process outcomes will be analyzed to determine whether the intervention is feasible for future dissemination and implementation efforts and recruitment of a full-scale randomized controlled trial.

  3. Acceptability (Aim 1)

    Time frame: Up to day 42

    Acceptability will be assessed by the Theoretical Framework of Acceptability (TFA) questionnaire and three additional quality improvement questions. To analyze intervention acceptability, scores on the TFA questionnaire will be calculated using the total mean score of seven TFA items. In this study, will use a cutoff of >= 70% of patients agreeing (or rating as confident, liking, acceptable or 4 out of 5 or higher on the TFA) as being acceptable for use.

  4. Satisfaction (Aim 1)

    Time frame: Up to day 42

    Satisfaction will be assessed by using three items assessing overall satisfaction. Satisfaction thresholds will require an average or mean of 7 out of 10 on each of the three items.

  5. Change in spiritual, religious, and existential (SRE) distress as measured by the Religious and Spiritual Struggles Scale-5 (RSS-5) (Aim 2)

    Time frame: At baseline and 1- and 6-week follow-up (days 42 and 84)

    Spiritual, religious, and existential (SRE) distress will be measured using the Religious and Spiritual Struggles Scale-5 (RSS-5), a valid and reliable 5-item Likert-type self-report measure of spiritual struggle. Each item is rated on a 5-point scale ranging from 1 ("not at all") to 5 ("a great deal"). Item scores are summed or averaged to create an overall SRE distress score. Total mean score ranges from 1 to 5, with higher scores indicating greater levels of SRE distress. Change in SRE distress will be assessed at baseline and at 1- and 6-week follow-up.

Secondary outcomes

  1. Change in self-transcendence as measured by the Self-Transcendence Scale (STS) (Aim 2)

    Time frame: At baseline and 1- and 6-week follow-up (days 42 and 84)

    Self-transcendence will be measured using the Self-Transcendence Scale (STS), a validated 15-item Likert-type self-report measure assessing individuals' sense of connection to something greater in 4 realms (intrapersonal, interpersonal, temporal and transpersonal). Each item is rated on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"), and item scores are summed or averaged to generate an overall self-transcendence score. Total mean score ranges from 1 to 4, with higher scores indicating greater levels of self-transcendence. Change in self-transcendence will be assessed at baseline and at 1- and 6-week follow-up.

  2. Change in psychological distress as measured by the Patient Health Questionnaire-8 (PHQ-8) (Aim 2)

    Time frame: At baseline and 1- and 6-week follow-up (days 42 and 84)

    Psychological distress will be measured using the Patient Health Questionnaire-8 (PHQ-8), a well-validated 8-item Likert-type self-report measure of depressive symptoms commonly used in cancer populations. Each item is rated on a 4-point scale ranging from 0 ("not at all") to 3 ("nearly every day"), and all items are summed to produce a total score. Total scores can range from 0 to 24, with higher scores indicating greater levels of psychological distress. Change in distress will be assessed at baseline and at 1- and 6-week follow-up.

  3. Change in anxiety as measured by Generalized Anxiety Disorder-7 (GAD-7) (Aim 2)

    Time frame: At baseline and 1- and 6-week follow-up (days 42 and 84)

    Anxiety will be measured using the Generalized Anxiety Disorder-7 (GAD-7), a validated 7-item Likert-type self-report measure of anxiety severity. Each item is rated on a 4-point scale ranging from 0 ("not at all") to 3 ("nearly every day"), and item scores are summed to create a total anxiety score. Total scores can range from 0 to 21, with higher scores indicating greater levels of anxiety. Change in anxiety will be assessed at baseline and at 1- and 6-week follow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

RaeAnne Wiseman

CONTACT

[email protected]

206-606-8215

Sponsors and collaborators

Lead sponsor

Fred Hutchinson Cancer Center

Other

Registry information

Official study title

Personal Archetypes Toward Healing (PATH) Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Apr 22, 2026
Registry last updated
Jun 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.